<DOC>
	<DOCNO>NCT02305953</DOCNO>
	<brief_summary>Psoriasis inflammatory disease involve skin , joint vascular compartment . The mechanisms link inflammation skin joint vascular wall poorly understood . One hypothesis increase vascular inflammation observe patient psoriasis involve circulate pro-inflammatory cytokine . Patients psoriasis increase serum level tumor necrosis factor alpha ( TNF-alpha ) , Interleukin-17 ( IL-17 ) , IL-22 , IL-6 well chemokine S100A913 . It possible one cytokines/chemokine induce vascular inflammation vascular compartment . The purpose cross sectional retrospective study highlight correlation vascular wall inflammation use 18F-2-fluoro-2-deoxy-D-glucose - Positron Emission Tomography ( FDG-PET ) fluorodeoxyglucose technology pro-inflammatory cytokines/chemokine .</brief_summary>
	<brief_title>Cytokines Vascular Inflammation Psoriasis</brief_title>
	<detailed_description>Baseline frozen serum sample identify 107 enrol Inno-6025 ( Abbvie A13-935 ) ( ClinicalTrials.gov Identifier NCT01722214 ) patient also underwent pre-adalimumab FDG-PET scan study . Serum cytokine chemokine level sample measure ; IL-17 IL-22 use Singulex immunoassay platform , S100A9 , IL-6 TNF alpha use multiplex ELISA . Vascular inflammation measure target background ratio ( TBR ) ascend aorta use PET-scan technology . Correlation analyse perform serum level cytokine chemokine vascular inflammation .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<criteria>1 . Patient plaque psoriasis . 2 . Patient least 6 month history plaque psoriasis . 3 . Patient Body Surface Area ( BSA ) cover psoriasis 5 % Day 0 . 4 . Patient candidate systemic therapy . 5 . Patient male female , 18 80 year age time consent . 6 . Patient 's weight screen maximum 180 kg . 7 . Patient use medication control angina , hypertension , serum lipid medication effect inflammation must stable dose least 8 week Day 0 . 8 . Patient ascend aorta atherosclerotic plaque inflammation targettobackground ratio 1.6 determine 18FDG uptake measure PET scan . 9 . Patient patient 's partner menopausal state least year , surgically sterile ( hysterectomy , bilateral oophorectomy , tubal ligation vasectomy ) , clinically diagnose infertile , samesex partner , abstinent , willing use effective contraceptive method least 30 day Day 0 least 6 month last study drug administration . Effective contraceptive method : 1 . Barrier method condom , sponge diaphragm combine spermicide foam , gel cream ; 2 . Hormonal contraception ( oral , intramuscular , implant transdermal ) include DepoProvera , Evra Nuvaring ; 3 . Intrauterine device ( IUD ) ; 10 . Female patient childbearing potential must negative serum pregnancy test Screening visit . 11 . Patient judge good general health determine principal investigator base upon result medical history , laboratory profile , physical examination , Chest XRay ( CXR ) perform Screening . 12 . Patient evaluate latent TB infection purify protein derivative ( PPD ) Quantiferon Gold test CXR . Patient demonstrate evidence latent TB infection ( either PPD equal 5 mm induration positive Quantiferon Gold , irrespective Bacillus CalmetteGuerin ( BCG ) vaccination status negative CXR finding active TB , and/or suspicious CXR finding ) allow participate study . 13 . Patient must able willing provide write informed consent comply requirement study protocol . 14 . Patient must able willing selfadminister subcutaneous ( SC ) injection qualify person available administer SC injection . 1 . Patient spontaneously improve rapidly deteriorate plaque psoriasis . 2 . Patient active infection ( bacterial , fungal viral ) skin diseases skin infection ( bacterial , fungal , viral ) may interfere evaluation psoriasis patient 's safety . 3 . Patient history allergic reaction significant sensitivity constituent study drug , include latex ( component prefilled syringe ) . 4 . Patient use nonbiological systemic therapy treatment psoriasis le 30 day Day 0 . 5 . Patient use investigational chemical biological agent le 30 day 5 halflives prior Day 0 visit ( whichever longer ) . 6 . Patient use biological therapy treatment psoriasis le 90 day day 0 . 7 . Patient use systemic immunosuppressor ( eg . Azathioprine , 6mercaptopurine ) less 30 day Day 0 . 8 . Patient take require oral injectable corticosteroid study . Inhaled corticosteroid stable medical condition allow . 9 . Patient use topical treatment psoriasis use phototherapy within last 2 week prior Day 0 ( exception low potency topical corticosteroid groin , genitals , face , inframammary area , palm sol ) . 10 . Patient receive Anakinra/Kineret within last 2 week prior Day 0 visit likely receive Anakinra/Kineret course study 11 . Patient poorly control medical condition , uncontrolled diabetes , document history recurrent infection , unstable ischemic heart disease , class III IV ( New York Heart Association Functional Classification ; NYHA ) congestive heart failure , ejection fraction le 30 % , recent stroke ( within past 3 month ) , chronic leg ulcer condition , opinion investigator , would put patient risk participate study . 12 . Patient myocardial infarction hospitalize cardiac condition within past 12 week . 13 . Patient history acute coronary syndrome , percutaneous coronary intervention , coronary artery bypass graft , carotid endarterectomy , stent installation carotid revascularization within 12 week Day 0 . 14 . Patient percutaneous coronary intervention past 12 month . 15 . Patient plan change medical treatment angina , serum lipid , hypertension medication significant effect inflammation course study . 16 . Patient history neurologic symptom suggestive central nervous system ( CNS ) demyelinate disease ( e.g . optic neuritis , visual disturbance , gait disorder/ataxia , facial paresis , apraxia ) . 17 . Patient history cancer lymphoproliferative disease successfully treat nonmetastatic cutaneous squamous cell basal cell carcinoma and/or localize carcinoma situ cervix . 18 . Patient history listeriosis , treat untreated Tuberculosis ( TB ) , persistent chronic infection , recent active infection require hospitalization treatment intravenous antiinfectives within 30 day prior Day 0 visit oral antiinfectives within 14 day prior Day 0 visit . 19 . Patient receive live attenuate vaccine 28 day less Day 0 plan receive live attenuate vaccine study 4 month last study drug administration.. 20 . Patient hepatitis B hepatitis C viral infection 21 . Patient follow : hemoglobin ≤ 10 g/L , white blood cell count ≤ 3.0 X 109/L , platelet count ≤130 X 10^9/L , alanine transaminase ( ALT ) ≥ 2 time upper limit normal , aspartate transaminase ( AST ) ≥ 3 time upper normal limit , total bilirubin ≥ 2 time upper normal limit creatinine ≥ 150 µmol/L . 22 . Patient currently use plan use antiretroviral therapy time study . 23 . Patient know immune deficiency immunocompromised . 24 . Female patient pregnant breastfeeding consider become pregnant study 6 month last dose study medication . 25 . Patient history clinically significant drug alcohol abuse last year . 26 . Patient plan travel area tuberculosis endemic study 4 month last study drug administration . 27 . Patient consider investigator , reason , unsuitable candidate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Vascular Inflammation</keyword>
	<keyword>Coronary Atherosclerosis</keyword>
	<keyword>Ascending aorta</keyword>
	<keyword>PET scan</keyword>
	<keyword>Cytokine</keyword>
	<keyword>Chemokine</keyword>
</DOC>